Fund Evaluator:
Defiance Autism Impact ETF (ASD)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$0.000
NAV (as of )
$0.00
Minimum Initial
0.79% F
Expense Ratio
$1 Mil
Assets
Open
Status
0.00%
12b-1 Fee
na
TTM Yield
0.00%
Max Load
na
Portfolio Turnover
Best Performing in Health Over the Last Year
| 62.8% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 62.6% | Fidelity Advisor Biotechnology I (FBTIX) |
| 56.2% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 53.5% | Fidelity Select Biotechnology (FBIOX) |
| 49.5% | Fidelity Select Pharmaceuticals Port (FPHAX) |
Data as of 7/31/2026
-1.4% D
1-Mo Return
na
3-Mo Return
na
YTD Return
na
1-Yr Return
na
3-Yr Return
na
5-Yr Return
na
Category Risk Index
na
Total Risk Index
Fund Details
Fund Family
Defiance ETFs LLC
Inception Date
6/1/2026
Share Class Type
Equity Investment Style
Mid-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
Yes
Index Fund
Yes
Benchmark Index
VettaFi Autism Impact TR USD: 100%
Additional Fund Details
Defiance Autism Impact ETF Overview
ASD Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| ASD Return (NAV) | -1.4% | na | na | na | na | na |
| ASD Grade | D | na | na | na | na | na |
| +/- Category | -1.1% | na | na | na | na | na |
| Health Avg | -0.4% | 10.7% | 33.9% | 10.7% | 5.0% | 9.3% |
| ASD Tax Cost Ratio | na | na | na | na | na | na |
ASD Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| ASD Return (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| ASD Grade | na | na | na | na | na | na | na | na | na | na | na |
| +/- Category | na | na | na | na | na | na | na | na | na | na | na |
| Health Avg | 7.1% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | na |
| Total Risk Index: | na |
| Category Risk Index: | na |
| Category Risk Grade: | |
| Beta: | na |
| R-Squared: | na |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Mid-Cap Blend |
| Bond Investment Style: | na |
| Yield: | -- |
| Dividend Distribution: | Annually |
| Cap Gains Distribution: | Annually |
| Total Assets: | $1 Mil |
| Fund Total Assets: | $ 1 Mil |
| Share Class Type: | |
| Portfolio Turnover: | na |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 0.2 years | |||
| Average Tenure: 0.2 years | |||
| Managers (Year): Lewellyn Dustin (2026), Tong Ernesto (2026), Johanson Christine (2026) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 41 |
| % in Top 10 Holdings: | 31.2% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 38.8% |
Portfolio Allocation |
|
| Domestic Stock: | 61.0% |
| Foreign Stock: | 38.8% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.1% |
| Cash: | 0.2% |
Purchase Information
| Fund Family: | Defiance ETFs LLC |
| Phone Number: | 800-617-0004 |
| Website: |
| Status: | Open |
| Inception Date: | June 1, 2026 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | 0.00% |
Expenses and Fees | |
| Expense Ratio (%): | 0.79% ( Rating : Above Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Defiance Autism Impact ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.